Evommune (EVMN) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 2, 2026, will be held virtually, allowing shareholders to vote and ask questions online.

• Shareholders of record as of April 6, 2026, are eligible to vote on proposals and participate in the meeting.

• Two main proposals: election of two Class I directors and ratification of BDO USA, P.C. as independent auditor for 2026.

• Proxy materials are available online, and multiple voting methods are provided, including internet, phone, and mail.

Voting matters and shareholder proposals

• Proposal 1: Elect Luis Peña and Eugene A. Bauer, M.D. as Class I directors for terms expiring at the 2029 Annual Meeting.

• Proposal 2: Ratify BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Shareholders may submit proposals or director nominations for the 2027 meeting, following SEC and bylaw requirements.

Board of directors and corporate governance

• Board divided into three classes, with staggered three-year terms; currently eight members.

• Majority of directors are independent per NYSE standards; separation of Chair and CEO roles for enhanced oversight.

• Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.

• Board and committees met regularly in 2025, with high attendance.